BRUIN CLL-322 trial: what clinicians have said so far
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
- NCT04965493 ↗
- Active, not recruiting
- Loxo Oncology, Inc.
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on BRUIN CLL-322 (pirtobrutinib in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on BRUIN CLL-322 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 2 posts on X, typically up to 9 once built | |
| 1 YouTube video, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
- Interventions
- Pirtobrutinib; Venetoclax; Rituximab
- Arms
- Arm A (PVR) · Experimental
- Arm B (VR) · Active comparator
- Enrollment
- 600 (estimated)
- Primary outcomes
- To evaluate progression-free survival (PFS) of pirtobrutinib plus venetoclax and rituximab (Arm A) compared to venetoclax and rituximab (Arm B)
- Sponsor
- Loxo Oncology, Inc. with Eli Lilly and Company
- Start
- Sep 20, 2021
- Primary completion
- Oct 2026 (estimated)
- Results posted
- No
- Registry record
- NCT04965493 · updated Jan 29, 2026
Publications
linked from the registry- Davids MS, Eyre TA, Woyach JA, Roeker LE, Ferrajoli A, Wang Y, Tam CS, Jurczak W, Zinzani PL, Simkovic M, Li JY, Bosch F, Roos-Weil D, Cramer P, Osterborg A, Islam P, Jacobs R, Skarbnik A, Bhat SA, Kang S, Chen M, Nguyen B, McNeely SC, Chung KL, Oliveira JM, Ito R, Ghia P, Wierda WG. Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet. 2026 Aug 1;408(10553):453-470. doi: 10.1016/S0140-6736(26)01204-3. Epub 2026 Jul 9. PubMed 42425121